CR2

Across TCGA pan-cancer cohorts, CR2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of CR2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CR2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CR2 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, COAD, and LUAD are the cancer types where CR2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CR2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−0.747	<.001	10	view →
COAD	All	III,IV	−1.625	<.001	9	view →
LUAD	Female	III,IV	−0.830	.004	3	view →
PDAC	Female	All	+0.481	.042	2	view →
LSCC	Male	II,III,IV	−0.310	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

CR2–CCRCC

Open the CCRCC breakdown →